Pharmaceuticals,
Journal Year:
2024,
Volume and Issue:
17(6), P. 689 - 689
Published: May 27, 2024
Public
perception
contrasts
scientific
findings
on
the
depression-related
effects
of
cannabis.
However,
earlier
studies
were
performed
when
cannabis
was
predominantly
illegal,
its
production
mostly
uncontrolled,
and
idea
medical
incipient
only.
We
hypothesized
that
recent
changes
in
attitudes
legislations
may
have
favorably
affected
research.
In
addition,
publication
bias
against
also
decreased.
To
investigate
this
hypothesis,
we
conducted
a
review
research
published
over
last
three
years.
found
156
relevant
articles.
most
cross-sectional
studies,
depression
higher
those
who
consumed
than
did
not.
An
increase
consumption
typically
followed
by
an
depression,
whereas
withdrawal
from
ameliorated
cases.
Although
reduced
none
these
placebo-controlled.
clinical
same
period,
placebo
and,
average
effect
size
larger
investigated
plausibility
antidepressant
reviewing
molecular
pharmacological
studies.
Taken
together,
reviewed
do
not
support
herbal
The Lancet Public Health,
Journal Year:
2025,
Volume and Issue:
10(2), P. e148 - e159
Published: Feb. 1, 2025
SummaryCannabis
consumption
is
legally
prohibited
in
most
countries
the
world.
Several
are
legalising
cannabis
for
adult
consumption.
It
important
to
monitor
public
health
effects
of
these
policy
changes.
In
this
paper,
we
summarise
evidence
date
on
legalisation
non-medical
use
Canada
and
USA.
We
describe
regulatory
models
legalisation,
changes
products
pricing,
illicit
market,
use,
cannabis-related
physical
mental
harms.
discuss
challenges
assessing
outcomes
emphasise
importance
continuous
rigorous
monitoring
adverse
inform
design
policies
regulations.
Addictive Behaviors,
Journal Year:
2023,
Volume and Issue:
144, P. 107740 - 107740
Published: April 24, 2023
Cannabis
potency
(concentration
of
Δ-9-Tetrahydrocannabinol)
has
been
associated
with
risks
adverse
mental
health
outcomes
and
addiction
but
no
studies
have
triangulated
evidence
from
self-report
objective
measures
cannabis
potency.
We
hypothesised
that
users
high
would
higher
levels
(a)
anxiety,
(b)
depression
(c)
psychosis-like
symptoms
(d)
dependence
than
lower
cannabis.A
cross-sectional
study
410
participants
donated
a
sample
for
analysis
THC
concentration
reported
their
preference.
These
two
exposure
were
investigated
association
dependence,
depression,
in
separate
linear/logistic
regression
models.High
preference
was
slight
increased
risk
after
adjusting
confounding,
the
exception
use
frequency
(OR
=
1.16,
95%
CI
1.04-1.28).
No
found
between
dependence.
There
weak
small
anxiety.
or
symptoms.Users
who
preferred
types
might
be
at
problematic
use.
This
should
considered
caution
as
we
not
able
to
triangulate
these
results
an
measure
More
research
is
needed
understand
Scientific Reports,
Journal Year:
2025,
Volume and Issue:
15(1)
Published: Feb. 4, 2025
The
Australian
Capital
Territory
(ACT),
a
region
that
includes
Australia's
capital,
Canberra,
decriminalised
small-scale
cannabis
cultivation
and
possession
in
January
2020.
Here,
we
examined
use
behaviours,
experiences
attitudes
of
current
past
ACT
cultivators.
residents
(n
=
311)
who
currently
cultivate
or
have
previously
cultivated
completed
cross-sectional
online
survey
('CAN-ACT')
provided
home-grown
for
phytocannabinoid
analysis
(optional).
Reasons
included
preference
to
self-supply,
enjoyment
the
process
avoiding
criminal
networks.
Cannabis
intake
was
median
1
gram
on
typical
day
used
number
plants
grown
per
year
4.
Various
challenges
were
identified,
most
commonly
mould,
nutrient
deficiency
spider
mites.
samples
71)
generally
exhibited
moderate
THC
content
(mean
8.99
±
SEM
0.51%
[w/w])
low
CBD
(<
0.1%).
Few
exceeded
contaminant
guidelines
heavy
metals
pesticides.
Respondents
identified
various
grey
areas
legislation
might
lead
inadvertent
activity,
many
(52%)
remained
anxious
about
arrest.
In
general,
recent
legislative
changes
appear
support
community
needs.
Options
further
refinement
are
discussed.
Substance Use & Misuse,
Journal Year:
2025,
Volume and Issue:
unknown, P. 1 - 10
Published: Feb. 16, 2025
Background
Variation
in
policy
design
presents
a
challenge
for
understanding
the
positive
and
negative
externalities
of
cannabis
legalization.
We
offer
an
advancement
on
measuring
state
variation
–
bundles
demonstrate
how
measure
can
be
used
to
test
effects
legalization
youth
mental
health.
Research Square (Research Square),
Journal Year:
2025,
Volume and Issue:
unknown
Published: March 26, 2025
AbstractBackground:
Suicide
rates
continue
to
rise,
especially
among
young
people,
and
is
considered
one
of
the
world's
leading
causes
death.
Suicidal
ideation
represents
a
significant
risk
factor
for
mortality,
particularly
cannabis
users.
Aim:
The
primary
objective
this
study
evaluate
suicide
students,
those
who
use
cannabis.
Methods:In
quantitative
study,
we
utilized
M.I.N.I.
questionnaire
gather
data
on
mental
disorders,
including
suicidal
risk.
was
administered
students
at
Abdelmalek
Essaâdi
University
campus
in
Tetouan,
with
an
average
age
21,
which
52.56%
were
female.
Along
questionnaire,
included
background
that
collected
socio-demographic
information,
history
psychoactive
substance
use,
family
background,
early
childhood
experiences
identify
factors
associated
each
disorder
under
investigation.
Results:
In
sample
1191
322
number
presenting
prevalence
27.03%,
41.7%
are
Conclusions:
line
previous
studies,
can
lead
thoughts
behaviors.
Biosensors,
Journal Year:
2024,
Volume and Issue:
14(3), P. 126 - 126
Published: Feb. 27, 2024
An
increasing
number
of
countries
have
started
to
decriminalize
or
legalize
the
consumption
cannabis
for
recreational
and
medical
purposes.
The
active
ingredients
in
cannabis,
termed
cannabinoids,
affect
multiple
functions
human
body,
including
coordination,
motor
skills,
memory,
response
time
external
stimuli,
even
judgment.
Cannabinoids
are
a
unique
class
terpeno-phenolic
compounds,
with
120
molecules
discovered
so
far.
There
certain
situations
when
people
under
influence
may
be
risk
themselves
public
safety.
Over
past
two
decades,
there
has
been
growing
research
interest
detecting
cannabinoids
from
various
biological
matrices.
is
need
develop
rapid,
accurate,
reliable
method
oral
fluid
as
it
can
reveal
recent
intake
comparison
urine
specimens,
which
only
show
history
consumption.
Significant
improvements
continuously
made
analytical
formats
technologies,
mainly
concerning
improving
their
sensitivity,
miniaturization,
making
them
more
user-friendly.
Additionally,
sample
collection
pretreatment
extensively
studied,
specific
devices
collecting
specimens
perfected
allow
rapid
effective
collection.
This
review
presents
findings
regarding
use
preferred
matrix
cannabinoid
detection
point-of-care
biosensor
diagnostic
device.
A
critical
presented,
discussing
articles,
well
publicly
available
data
companies
that
manufacture
screening
devices.
Firstly,
conventional
methods
used
detect
matrices
presented.
Secondly,
using
biosensors
discussed,
emphasizing
specimens.
current
pressing
technological
challenges
highlights
gaps
where
new
solutions
implemented.
Frontiers in Public Health,
Journal Year:
2024,
Volume and Issue:
12
Published: May 22, 2024
Background
As
the
most
commonly
used
illicit
substance,
cannabis
is
gaining
global
acceptance
through
increasing
legalization
efforts.
This
shift
intensifies
need
for
research
to
guide
policymakers
and
healthcare
providers
in
harm
reduction
treatment
strategies.
Nonetheless,
relationship
between
psychopathological
symptoms
use
remains
inadequately
understood.
Methods
A
sample
of
regular
consumers
completed
self-reported
assessments
depression
(Patient
Health
Questionnaire-9),
anxiety
(General
Anxiety
Disorder-7),
Attention-Deficit/Hyperactivity
Disorder
(ADHD;
Adult
ADHD
Self-Report
Scale
V1.1),
psychosis
(Early
Recognition
Inventory
based
on
IRAOS)
as
well
previous
black-market
patterns.
Cannabis
Use
Identification
Test
Revised
(CUDIT-R)
was
identify
disorder
(CUD).
To
understand
symptom
load
related
consumption
motives,
multiple
regression
models
were
performed
variables
predicting
frequency
quantity.
Linear
correlation
analyses
conducted,
adjusting
relevant
covariates
(age,
gender,
education,
alcohol,
other
substance
use).
Results
Three-hundred-sixty
users
interested
a
study
regulated
access
Basel,
Switzerland
examined.
In
bivariate
analysis,
correlated
with
depressive
(
r
(358)
=
0.16,
p
0.003)
0.11,
0.034).
quantity
0.15,
0.005),
0.14,
0.008),
0.002).
However,
adjusted
only
loads
significantly
associated
0.006
0.034,
respectively)
0.037
0.019,
respectively).
No
significant
correlations
or
remained
after
adjustment.
Conclusion
correlate
increased
cohort
users,
suggesting
potential
self-medication
nonclinical
populations.
With
rising
availability
worldwide,
these
results
highlight
necessity
longitudinal
studies
disentangle
complex
dynamics
mental
health
symptoms.
Public
perception
contrasts
scientific
findings
on
the
depression-related
effects
of
cannabis.
However,
earlier
studies
were
performed
when
cannabis
was
predominantly
illegal,
its
production
mostly
uncontrolled,
and
idea
medical
incipient
only.
We
hypothesized
that
recent
changes
in
attitudes
legislations
may
have
favorably
affected
research.
In
addition,
publication
bias
against
also
decreased.
To
investigate
this
hypothesis,
we
conducted
a
systematic
review
research
published
over
last
three
years.
found
156
relevant
studies.
most
cross-sectional
studies,
depression
higher
those
who
consumed
than
did
not.
An
increase
consumption
typically
followed
by
an
depression,
whereas
withdrawal
from
ameliorated
cases.
Albeit
reduced
none
these
placebo
controlled.
clinical
same
period,
average
effect
size
larger
investigated
plausibility
antidepressant
reviewing
molecular
pharmacological
Taken
together,
reviewed
do
not
support
herbal
